盐酸伊托必利缓释片在犬体内的药动学  

Pharmacokinetics study on sustained-release tablets of itopride hydrochloride on healthy dogs

作　　者：康艳萍[1] 文万江 金圣煊[3] 毕殿洲[3] 

机构地区：[1]宜春学院化学与生物工程学院,江西宜春336000 [2]金华康恩贝生物制药有限公司,浙江金华321016 [3]沈阳药科大学药学院,辽宁沈阳110016

出　　处：《中国医院药学杂志》2008年第12期984-986,共3页Chinese Journal of Hospital Pharmacy

摘　　要：目的:对盐酸伊托必利缓释片和分散片在家犬体内进行药动学研究。方法:6只家犬按照单剂量双周期实验设计方案给药,建立一个测定狗血中的伊托必利的高效液相色谱法。结果:2种制剂在体内均符合单隔室一级吸收模型,缓释片和分散片Cmax分别为(548.6±54.2)μg·L-1和(798.1±42.5)μg·L-1,tmax分别为(6.7±1.2)h和(1.83±0.25)h,应用3P97药动学程序进行计算,t1/2(Ke)分别为(6.0±0.6)h和(5.72±0.26)h,AUC0-∞分别为(6.6±0.5)mg·L-1·h和(7.0±0.6)mg·L-1·h。结论:盐酸伊托必利缓释片具有显著缓释作用。OBJECTIVE The pharmacokinetics was studied on sustained-release tablets of itopride hydrochloride using health dogs and was compared with the dispersible tablets of itopride hydroehloride. METHODS A single dose of the sustained-release dispersible tablets of itopride hydrochloride were given separately to six dogs according to the double-periodical crossed design. An HPLC method was established for the determination of the plasma concentration of itopride hydrochloride. RESULTS After oral administration, the pharmacokinetics parameters of sustained-release tablets Cmax tmax, t1/2（Ke）, AUC0→∞ were （548. 6 ± 54. 2） μg·L^-1 , （6. 7 ＋ 1.2）h, （6. 0± 0. 6）h and （6. 6± 0. 5）mg·L^-1·h respectively, and the corresponding parameters of dispersible tablets were（798.1± 42.5）μg·L^-1 , （1.83 ±0. 25）h, （5. 72 ± 0. 26）h and （7.0± 0. 6）mg·L^-1·h CONCLUSION The sustained-release tablets of itopride hydrochloride have an significant sustained-released effect.

关 键 词：盐酸伊托必利 缓释片 药物动力学 

分 类 号：R969.1[医药卫生—药理学]